Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03549715
Title NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma (NEMIO)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Association Pour La Recherche des Therapeutiques Innovantes en Cancerologie

invasive bladder transitional cell carcinoma

prostatic urethra urothelial carcinoma


Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Tremelimumab + Vinblastine

Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Vinblastine

Age Groups: adult | senior
Covered Countries FRA

No variant requirements are available.